The company’s platform uses machine learning and metabolomics to identify new compounds. Enveda will use the financing to advance the leading compounds to the clinical stage, according to a Dec. 21 Enveda news release.
Dimension led the funding round that brought the company’s total capital raised to $124 million.
“While we are prioritizing building and advancing our internal pipeline, we will continue to forge partnerships with industry-leading pharmaceutical and biotech companies in a variety of therapeutic areas, including inflammation, fibrosis, and other chronic diseases.” Enveda Chief Business Officer Vanitha Sekar, PhD, said.
